TY - JOUR
T1 - Ovarian Cancer Radiosensitivity
T2 - What Have We Understood So Far?
AU - Barcellini, Amelia
AU - Charalampopoulou, Alexandra
AU - De Cecco, Loris
AU - Fodor, Andrei
AU - Rabaiotti, Emanuela
AU - Candotti, Giorgio
AU - Secondino, Simona
AU - Facoetti, Angelica
AU - Locati, Laura Deborah
AU - Pignata, Sandro
AU - Orlandi, Ester
AU - Mangili, Giorgia
N1 - Funding Information:
S.P. declares honoraria and research funding from AZ MSD GSK. The other authors declare that they have no competing interests related to the present study.
Publisher Copyright:
© 2022 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - Radiotherapy has been increasingly considered as an active treatment to combine with other approaches (i.e., surgery, chemotherapy, and novel target-based drugs) in ovarian cancers to palliate symptoms and/or to prolong chemotherapy-free intervals. This narrative review aimed to summarize the current knowledge of the radiosensitivity/radioresistance of ovarian cancer which remains the most lethal gynecological cancer worldwide. Indeed, considering the high rate of recurrence in and out of the radiotherapy fields, in the era of patient-tailored oncology, elucidating the mechanisms of radiosensitivity and identifying potential radioresistance biomarkers could be crucial in guiding clinical decision-making.
AB - Radiotherapy has been increasingly considered as an active treatment to combine with other approaches (i.e., surgery, chemotherapy, and novel target-based drugs) in ovarian cancers to palliate symptoms and/or to prolong chemotherapy-free intervals. This narrative review aimed to summarize the current knowledge of the radiosensitivity/radioresistance of ovarian cancer which remains the most lethal gynecological cancer worldwide. Indeed, considering the high rate of recurrence in and out of the radiotherapy fields, in the era of patient-tailored oncology, elucidating the mechanisms of radiosensitivity and identifying potential radioresistance biomarkers could be crucial in guiding clinical decision-making.
KW - ovarian cancer
KW - radiation
KW - radiobiology
KW - radioresistance
KW - radiosensitivity
UR - http://www.scopus.com/inward/record.url?scp=85146519611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146519611&partnerID=8YFLogxK
U2 - 10.3390/life13010006
DO - 10.3390/life13010006
M3 - Review article
AN - SCOPUS:85146519611
SN - 0024-3019
VL - 13
JO - Life
JF - Life
IS - 1
M1 - 6
ER -